Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

PURPOSE: PRIMARYS (NCT00690898) was a 48-week, open-label, phase 3b study, evaluating treatment with the somatostatin receptor ligand lanreotide autogel (stable dose: 120 mg/28 days) in treatment-naïve patients with growth hormone (GH)-secreting pituitary macroadenoma. This post hoc analysis aimed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Caron, Philippe J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066297/
https://www.ncbi.nlm.nih.gov/pubmed/31879842
http://dx.doi.org/10.1007/s11102-019-01020-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066297/
https://www.ncbi.nlm.nih.gov/pubmed/31879842
http://dx.doi.org/10.1007/s11102-019-01020-3

Ejemplares similares